PharmaMar
Spanish pharmaceutical company
BME Madrid
ISIN ES0169501022 LEI 959800QWKZ45ZQC2AV58
Follow PharmaMar
Weekly email: filings, results
Revenue, last year
€221.4M
+26.6% vs prior year
Net income
€75M
+187% vs prior year
EPS, diluted
€4.30
+188.6% vs prior year
Operating cash flow
€53.1M
+781.5% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €221.4M | €75M |
| FY24 | €174.9M | €26.1M |
| FY23 | €158.2M | €1.1M |
| FY22 | €196.3M | €49.4M |
| FY21 | €229.8M | €92.9M |
| FY20 | €270M | €137.3M |
| FY19 | €85.8M | −€11.4M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 94.5% | 27.4% | 33.9% |
| FY24 | 95.3% | 3.7% | 14.9% |
| FY23 | 93.9% | −2.4% | 0.7% |
| FY22 | 93.1% | 22.4% | 25.1% |
| FY21 | 92.8% | 40.2% | 40.4% |
| FY20 | 94.9% | 57.8% | 50.8% |
| FY19 | 93.9% | −20.4% | −13.3% |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | €13.9M | €34.1M |
| FY24 | €11.4M | €18.6M |
| FY23 | €11.7M | €37.9M |
| FY22 | €11.8M | €50.2M |
| FY21 | €10.9M | €40.7M |
| FY20 | €8.8M | €63.7M |
| FY19 | €0 | €7.5M |
- PharmaMar
- Healthcare median
Show the numbers
| Year | PharmaMar | Healthcare median |
|---|---|---|
| FY25 | 33.9% | −30.6% |
| FY24 | 14.9% | −47% |
| FY23 | 0.7% | −58% |
| FY22 | 25.1% | −80.4% |
| FY21 | 40.4% | −71.9% |
| FY20 | 50.8% | −62.2% |
| FY19 | −13.3% | −46.3% |